Development of a plasma- and albumin -free recombinant von Willebrand factor
Mitterer, A.; Matthiessen, H.-P.; Gritsch, H.; Varadi, K.; Siekmann, J.; Schnecker, K.; Plaimauer, B.; Kaliwoda, M.; Purtscher, M.; Woehrer, W.; Mundt, W.; Muchitsch, E.-M.; Suiter, T.; Ewenstein, B.-M.; Ehrlich, H.-J.; Schwarz, H.-P.; Turecek, P.-L. · Zeitschrift für Orthopädie und Unfallchirurgie · 2009 · Heft S 01 · S. S32-S38
Bibliografische Angaben
Zusammenfassung
SummaryBaxter has developed a recombinant therapy for treating von Willebrand‘s disease. Recombinant VWF is co-expressed with the rFVIII in CHO cells used to produce the rFVIII product Advate. This rVWF is used as a drug component for a rVWF-rFVIII complex drug product. CHO cells produce partially processed and partially un-processed rVWF still containing the pro-peptide. In order to make a consistent preparation containing mature and processed rVWF only, rVWF is exposed to recombinant furin to remove the pro-peptide. Recombinant
